Meridian Bioscience Shares Volatile But Largely Unch Following News FY13 Sales Will Be at Low-End of Prior Range, FY14 Sales Expected $203-208M vs $205.6M Est, EPS $0.98-1.03 vs $1.01 Est.
Paul Quintaro